The main study of PHESGO was a comparison of PHESGO vs IV PERJETA (pertuzumab) + Herceptin (trastuzumab).*
The combined results of the study showed that there were no major differences between PHESGO and IV PERJETA + Herceptin.
*Some patients in the trial were given Herceptin HYLECTA® (trastuzumab and hyaluronidase-oysk) injections instead of Herceptin infusions during treatment after surgery.
85% preferred PHESGO (n=136); 14% preferred IV PERJETA + Herceptin (n=22); 1% had no preference (n=2)
The most common reason people preferred PHESGO was because it took less time in the clinic
The most common reason people preferred IV PERJETA + Herceptin was because it felt more comfortable during administration
Your doctor can answer any questions you have about PHESGO.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.